How would you manage rising PSA in a patient with de novo metastatic prostate CA with PSA nadir at < 0.2 with ADT and NHT?

Is there a role for PSMA PET imaging in this setting?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How can you manage a patient with bilateral PCNs who requires Pluvicto administration?

For patients with high-volume hormone-sensitive prostate cancer, would you consider shortening the docetaxel course to 4 cycles to facilitate better tolerance?

What are your top takeaways in GU Cancers from ESMO 2025?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.